LeonaBio director granted 28,000 stock options

LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock at an exercise price of $8.35 per share.

Rhea-AI Filing Summary

LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock at an exercise price of $8.35 per share. The options expire on June 22, 2036 and vest on the earlier of June 23, 2027 or the day before the next annual stockholder meeting after June 22, 2026, under the company’s Outside Director Compensation Policy.

Insider Trade Summary

Grant/Award: 28,000 shares

Grant/Award 1 txn

Insider EDELMAN JOSEPH

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

Key Figures

Option grant size: 28,000 shares Exercise price: $8.35 per share Expiration date: June 22, 2036 +1 more

4 metrics

Option grant size 28,000 shares Stock options on LeonaBio common stock granted to director Joseph Edelman

Exercise price $8.35 per share Strike price for Edelman’s stock option grant

Expiration date June 22, 2036 Expiration of Edelman’s stock options if not exercised

Latest possible vesting date June 23, 2027 Options vest on this date or earlier, depending on next annual meeting timing

Key Terms

Stock Option (Right to Buy), Outside Director Compensation Policy, Common Stock, Grant, award, or other acquisition

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Outside Director Compensation Policy financial

"The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy."

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LeonaBio (LONA) disclose for Joseph Edelman?

LeonaBio disclosed that director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock. This is a compensation-related award, not an open-market share purchase or sale, and is documented on a Form 4 insider transaction report.

How many LeonaBio (LONA) shares are covered by Joseph Edelman’s option grant?

The option grant to Joseph Edelman covers 28,000 shares of LeonaBio common stock. These options give the right, but not the obligation, to buy those shares at a fixed exercise price if and when the options vest and are exercised.

What is the exercise price of Joseph Edelman’s LeonaBio (LONA) stock options?

The exercise price for Joseph Edelman’s stock options is $8.35 per share. This means he can buy up to 28,000 LeonaBio common shares at $8.35 each once the options vest, regardless of the market price at that time.

When do Joseph Edelman’s LeonaBio (LONA) stock options vest?

Edelman’s options vest on the earlier of June 23, 2027, or the day immediately before the date of the next annual stockholder meeting that occurs after June 22, 2026. Vesting must occur before he can exercise the options to purchase shares.

When do Joseph Edelman’s LeonaBio (LONA) stock options expire?

The stock options granted to Joseph Edelman expire on June 22, 2036. After that expiration date, any unexercised options become worthless, so the potential right to buy LeonaBio shares at $8.35 per share ends on that date.

Is Joseph Edelman’s LeonaBio (LONA) option grant an open-market purchase?

No, the filing shows a grant of stock options as compensation, reported with transaction code A. Edelman did not buy shares in the open market; instead, he received options under LeonaBio’s Outside Director Compensation Policy at a set exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 06:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDELMAN JOSEPH

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.35	06/23/2026		A		28,000		(1)	06/22/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

	/s/ Mark Worthington, Attorney in fact for Joseph Edelman	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)